Mergers & Acquisitions ·
Jasper Therapeutics confirms that holders of its common stock as of the July 16, 2026 closing date of the Kira…
JSPRJasper Therapeutics, Inc.
Jasper Therapeutics confirms that holders of its common stock as of the July 16, 2026 closing date of the Kira Pharmaceuticals acquisition are entitled to one contractual contingent value right (CVR) per share. Each CVR entitles the holder to a pro rata portion of $30 million if the FDA issues a Priority Review Voucher for briquilimab on or before December 31, 2028. The rights are non-transferable and unregistered. Jasper Therapeutics operates in the biotechnology industry.